「NMDA」の共起表現一覧(1語右で並び替え)
該当件数 : 97件
Its | NMDA actions, similar to those of the phenylheptylam |
NMDA, AMPA kainate, mGluR1, mGluR2, mGluR3, mGluR4, | |
l experiments, Palazzo et al. demonstrated that | NMDA, an ionotropic glutamate receptor, and the meta |
ensory nerve terminals in the skin also express | NMDA and non-NMDA receptors. |
ty of several ion channels including the GABAA, | NMDA, and sigma receptors. |
ors it has been demonstrated to function on are | NMDA and the D1 dopamine receptor. |
ther ionotropic receptors for glutamate such as | NMDA and AMPA. |
It is a non-competitive | NMDA antagonist and calcium channel blocker |
a number of receptor systems, being both a weak | NMDA antagonist and a 5HT1A agonist. |
elucemine (NPS-1506) is a drug which acts as an | NMDA antagonist and a serotonin reuptake inhibitor, |
s a drug related to memantine, which acts as an | NMDA antagonist and has neuroprotective effects. |
as increased glucose metabolism in response to | NMDA antagonist exposure. |
.3x meperidine in potency) although it also has | NMDA antagonist properties like its close relative k |
tive than 18-MC with very little activity as an | NMDA antagonist and only slight affinity for the del |
red in combination with other drugs such as the | NMDA antagonist tiletamine or the alpha-2 adrenergic |
estinel (GV-150,526) is a drug which acts as an | NMDA antagonist, binding selectively to the glycine |
esonprodil (CI-1041) is a drug which acts as an | NMDA antagonist, selective for the NR2B subunit. |
iprodil (SL-82.0715) is a drug which acts as an | NMDA antagonist, binding to the polyamine modulatory |
is a drug developed by Pfizer which acts as an | NMDA antagonist, selective for the NR2B subunit. |
GS-19755) is a drug which acts as a competitive | NMDA antagonist, directly competing with glutamate f |
decahydroquinoline (8A-PDHQ) is a high affinity | NMDA antagonist. |
otel (EAA-090) is a drug which acts as a potent | NMDA antagonist. |
-1102) is a drug which acts as a noncompetitive | NMDA antagonist. |
ts and instead acts as a potent non-competitive | NMDA antagonist. |
ome apparent 2 hours after administration of an | NMDA antagonist. |
In animal models, | NMDA antagonists increase glutamate release in the p |
After repeated doses of the | NMDA antagonists MK-801 and PCP, the vacuolation rea |
I added dissociatives ( | NMDA antagonists) as psychedelics. |
MK-801, along with other | NMDA antagonists, induce the formation of brain lesi |
sions") occurred in brains of rats administered | NMDA antagonists, including PCP, MK-801 (dizocilpine |
antidepressant effect when co-administered with | NMDA antagonists. |
oxic changes corresponded with their potency as | NMDA antagonists: i.e. |
NMDA channel has been shown to be involved in long-t | |
Lacosamide does not affect AMPA, kainate, | NMDA, GABAA, GABAB or a variety of dopaminergic, ser |
NMDA receptor | |
(Tet-Gly, LY-285,265) is a potent and selective | NMDA receptor agonist, stimulating the NMDA receptor |
It also acts as an | NMDA receptor antagonist. |
Chemicals that deactivate the | NMDA receptor are called antagonists. |
Most | NMDA receptor antagonists are metabolized in the liv |
Dextrorphan - A dissociative hallucinogen ( | NMDA receptor antagonist) and cough suppressant. |
Frequent administration of most | NMDA receptor antagonists can lead to tolerance, whe |
2R)-amino-5-phosphonopentanoate) is a selective | NMDA receptor antagonist that competitively inhibits |
esthetic and pharmacologically classified as an | NMDA receptor antagonist. |
and that the cortical | NMDA receptor properties and membrane fluidity are a |
eceptor agonist, κ-opioid receptor agonist, and | NMDA receptor antagonist. |
AP-7 is a selective | NMDA receptor (NMDAR) antagonist that competitively |
It has also been shown to act as a low-affinity | NMDA receptor antagonist. |
Glutamate [ | NMDA] receptor subunit 3A is a protein that in human |
Glutamate [ | NMDA] receptor subunit epsilon-1 is a protein that i |
Glutamate [ | NMDA] receptor subunit epsilon-4 is a protein that i |
stulated that this is a homeostatic response to | NMDA receptor blockade, which in turn increases psyc |
It acts as an | NMDA receptor antagonist but has low potency and act |
CKA (5,7-dichlorokynurenic acid) is a selective | NMDA receptor (NMDAR) antagonist acting at the glyci |
e AMPA receptor antagonist, and non-competitive | NMDA receptor antagonist. |
Glutamate [ | NMDA] receptor subunit 3B is a protein that in human |
development of synaptic elements by modulating | NMDA receptor activity. |
As an | NMDA receptor antagonist, in vivo, it is approximate |
Other | NMDA receptor modulators are being studied and this |
NMDA receptor agonists like ibotenic acid (which is | |
Huperzine A is also a | NMDA receptor antagonist which protects the brain ag |
ing within in vitro preparations, and can block | NMDA receptor action at a reasonably small concentra |
NMDA receptor channels are heteromers composed of th | |
nervous system and has its mode of action as an | NMDA receptor antagonist. |
A class of | NMDA receptor antagonists have been denoted dissocia |
de of GlyT1 has been hypothesized to potentiate | NMDA receptor function in vivo and to represent a ra |
rent ability to stabilize disrupted or disabled | NMDA receptor pathways in the brain, which are share |
trorotary isomer, dextromethorphan, is a common | NMDA receptor antagonist and pro-drug to dextrorphan |
dies of glycine (and related co-agonists at the | NMDA receptor) added to conventional anti-psychotics |
Examples include haemoglobin (pictured), the | NMDA receptor, some aquaporins, some AMPA receptors, |
an receptor site is the PCP binding site in the | NMDA receptor, a type of ligand-gated ion channel. |
The induction of | NMDA receptor-dependent long-term potentiation (LTP) |
apse to an active one, since this conversion is | NMDA receptor-dependent. |
zoline I2 receptor antagonists reversibly block | NMDA receptor-mediated Ca2+ influx and thus may inhi |
PEAQX is a competitive antagonist at the | NMDA receptor. |
-physiological partial agonist of the mammalian | NMDA receptor. |
able AMPA receptor and kainate receptor but not | NMDA receptor. |
ith different subunits of N-methyl-D-aspartate ( | NMDA) receptor. |
antibodies to the delta2 or NR2 subunits of the | NMDA receptor. |
N-methyl-D-aspartate ( | NMDA) receptors are a class of ionotropic glutamate |
d her colleagues demonstrated the importance of | NMDA receptors in development plasticity. |
as a neuronal signaling molecule by activating | NMDA receptors in the brain. |
Glutamate opens | NMDA receptors on other neurons which allows calcium |
NMDA receptors start to become unresponsive, slowing | |
ulators of a variety of ion channels, including | NMDA receptors and AMPA receptors. |
eptor and imidazoline binding sites, and blocks | NMDA receptors and other cation ligand-gated channel |
r treatment focus because glutamate blocks some | NMDA receptors which, on their own, induce schizophr |
ffects on Aplysia long-term potentiation, since | NMDA receptors are required for both. |
encodes a subunit of the N-methyl-D-aspartate ( | NMDA) receptors, which belong to the superfamily of |
neurotrophic factor (BDNF), glutamate acting at | NMDA receptors, dopamine through activation of the D |
") and ketamine, both of which block glutamate ( | NMDA) receptors, are known to cause psychosis closel |
A and 5-HT2C), 5-HT6, 5-HT7, α1-adrenergic, and | NMDA receptors, and as agonists at the sigma recepto |
ying ovarian or mediastinal teratoma expressing | NMDA receptors. |
ls and has a low affinity for AMPA, kainate and | NMDA receptors. |
t a hypofunction of glutamatergic signaling via | NMDA receptors. |
holine antagonists, with little or no effect on | NMDA receptors. |
ol's acute effects on GABAergic enhancement and | NMDA suppression, leading to CNS depression leading |
kappa and delta opioid, sigma receptors, or the | NMDA system are not well understood. |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |
こんにちは ゲスト さん
ログイン |
Weblio会員(無料)になると 検索履歴を保存できる! 語彙力診断の実施回数増加! |